Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154848 | 0.85 | MEN1 (0.44) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL10396025 | 0.82 | MAPT (0.59) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL18154788 | 0.77 | KMT2A (0.40) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10517534 | 0.76 | MAPT (0.58) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL18154846 | 0.75 | MTOR (0.41) | DHFRROCK1 | |
| SCHEMBL18154713 | 0.74 | ALOX5AP (0.43) | SMN1; SMN2LMNARAB9AHTTDHFR | |
| SCHEMBL18154735 | 0.74 | HTR6 (0.42) | MEN1KMT2ALMNAALDH1A1RAB9A | |
| SCHEMBL4163474 | 0.73 | MAPT (0.79) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3328543 | 0.73 | MAPT (0.79) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL10521999 | 0.73 | ALDH1A1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3283482-A1 | PLK4 INHIBITORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166604-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | MAPT 3052/4885MEN1 3546/4885KMT2A 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.